The biggest risk is not technology failure but capture failure. Credo can execute well and still disappoint the stock if customer concentration stays high, if optical products qualify slower than hoped, or if larger platform vendors and
hyperscalers absorb too much of the economics. The balance sheet is strong, but the valuation leaves limited room for a pause in AI spending or a stumble in the transition from
AEC-led growth to a broader optical stack.